ClinicalTrials.gg
RecruitingNCT07135700DIRECT-HEARTUpdated Nov 4, 2026

Hemodynamic Evaluation and Assessment of DIRECT myocaRdial and Sublingual Capillary Perfusion in Thoracic Surgery Patients on Cardiopulmonary Bypass

An observational study in Microcirculatory Perfusion, sponsored by Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA). Recruiting at 1 site in Netherlands. Per ClinicalTrials.gov, last updated 2026-11-04.

Sponsored by Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) · Observational

How we know

Updated Nov 4, 2026Now RecruitingFirst site in Netherlands+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
30
Sex
All
01

Study summary

After cardiac surgery, some people may experience problems with their circulation or how well the heart pumps. This can occur because the smallest blood vessels in the heart do not function properly. When these vessels don't work correctly, organs and tissues don't receive enough oxygen and nutrients, which can lead to circulatory problems and organ damage.

Typically, treatments focus on improving the larger blood vessels, such as blood pressure and heart function, but the investigators don't yet know enough about the smallest blood vessels. In this study, the investigators measure blood flow using a special camera (a microscope) at two locations: under the tongue and directly on the heart. Measurements under the tongue are already performed more frequently, but measurements directly on the heart are still new.

If the investigators can demonstrate that differences in cardiac blood flow can also be observed under the tongue, it will become easier to conduct research on microcirculation. The use of the device is safe, and measurements are performed under strict supervision and control by experienced physicians and researchers.

Ultimately, the investigators hope to use this knowledge to better prevent or treat complications after cardiac surgery.

The aim of this research is to investigate whether measurements of blood flow in the smallest blood vessels (microcirculation) on the heart provide the same information as measurements of microcirculation under the tongue.

This appears to be describing a clinical study comparing sublingual and epicardial microcirculation monitoring techniques to potentially establish a less invasive method for assessing cardiac microvascular function in post-surgical patients.

Read the detailed description

Congruence of micro- and macrocirculation is essential in participants during the postcardiotomy period to maintain hemodynamic stability [1,2]. At the capillary (i.e. microcirculatory) level, gas and nutrient exchange occurs, while macrocirculation facilitates these exchanges by ensuring that blood flows with appropriate pressure and velocity. A mismatch in this relationship, where the capillary perfusion does not correlate with the macrocirculatory parameters, is frequently observed in patients with shock or heart failure [3,4]. This discrepancy is often caused by capillary leak or hemodilution. To date, treatment has primarily focused on correcting macroscopically observed variables or values derived from them and resulting in pressure- or flow-dependent therapies.

While sublingual capillary perfusion measurements provide systemic insights, direct myocardial capillary perfusion assessment offers a direct and regional perspective. Unlike systemic capillary beds, myocardial perfusion is directly influenced by filling pressures, such as left ventricular end-diastolic pressure (LVEDP) [5]. Impaired myocardial capillary perfusion can lead to a cascade of cardiac dysfunction, including reduced oxygen delivery, inadequate nutrient exchange and making it vulnerable to ischemia or hibernation [1].

Current literature has examined intra- and postoperative sublingual (i.e., systemic) capillary perfusion following cardiac surgery [5]. Cardiopulmonary bypass (CPB), commonly used in many types of heart surgeries, inherently disrupts capillary perfusion due to its extracorporeal nature. The use of CPB alone triggers systemic inflammation, reperfusion injury and hemodilution, leading to the accumulation of metabolic waste products, formation of free oxygen radicals and perfusion alternations [7]. Additionally, the participants undergo an invasive cardiac procedure, accompanied by anesthesia and other contributing factors that negatively impact the capillary perfusion [8]. These alterations manifest in differences in microcirculatory parameters, including total vessel density (TVD), perfused vessel density (PVD), proportion of perfused vessels (PPV), microvascular flow index (MFI), and heterogeneity index (HI) [9].

Additionally, unloading the left ventricle (LV) unloading is posited to be critical for improving myocardial circulation. LV unloading is a promising concept that theoretically could improve capillary perfusion by reducing LVEDP and hence myocardial work. LV unloading could be particularly important for heart failure patients in acute cardiogenic shock. It may help promote myocardial circulation and prevent pulmonary edema. However, there is currently no robust scientific evidence to support these benefits and remains a subject of debate and philosophical discourse within the medical community [11-13].

To address this, the investigators aim to investigate whether capillary perfusion changes induced by CPB flow alterations, measured at sublingual and myocardial sites, provide consistent results. Additionally, the investigators will assess the effect of LV unloading on the capillary perfusion. The investigators will employ a handheld IDF-microcamera to perform real-time measurements of capillary perfusion. The investigators hypothesize that during hemodynamic alternations via CPB-flow sublingual and myocardial capillary perfusion measurements will show minimal differences and correlate with each other. This would supporting the validity of sublingual capillary perfusion measurements as a reliable, non-invasive proxy for the myocardial capillary perfusion status. Furthermore, the investigators anticipate an improvement in solely myocardial of both sublingual and myocardial capillary perfusion with LV unloading. These findings will significantly advance our understanding of the interaction between macro- and microcirculatory systems, providing a foundation for the use of sublingual measurements in both clinical and research settings. Ultimately, this could simplify monitoring techniques, enhance perioperative management, and help elucidate the mechanisms underlying persistent hemodynamic instability, guiding the development of more effective strategies to optimize postoperative outcomes

02

Conditions studied

  • Microcirculatory Perfusion

Keywords

  • cardiac surgery
  • microcirculation
  • capillary perfusion
03

In context

Lead sponsor

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) is the lead sponsor of 533 studies on the registry; 182 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The patients are selected from the surgical waiting list. Since we aim to include only elective adult patients with minimal comorbidities and a low or intermediate European System for Cardiac Operative Risk Evaluation (EuroSCORE) II (i.e., low or intermediate risk of in-hospital mortality), a significant number of patients are eligible. On our department, we perform approximately 20 cardiac surgeries per week, with valve surgeries representing a relatively large portion. The distribution of surgeries varies from week to week. However, a significant proportion of patients cannot be included due to the need for concomitant coronary revascularization or a history of such procedures

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult patients (18 years or older)
  • Use of central cannulated CPB through median sternotomy
  • Patients undergoing valve surgery or a supracoronary ascending aorta replacement
  • Good and RVF
  • LAVI \< 50 ml/m2, and right atrial volume index (RAVI) \< 45 ml/m2,

Exclusion criteria

Exclusion Criteria:

  • Patients with significant coronary artery disease (i.e., CAD-RADS ≥ 4, and/or stenosis of ≥ 70% as observed in coronary angiogram) or previous infarctions, including ST-elevated myocardial ischemia (STEMI) or non-ST-elevated myocardial ischemia (N-STEMI)
  • Patients with echocardiographically observed regional wall motion abnormalities, hypokinesis, or akinesis in the coronary territories
  • Patients undergoing left atrial appendage amputation (LAAA)
  • Patients with AF
  • High-risk patients, as defined by a EuroSCORE II ≥ 8%
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
30 participants (estimated)
Patient registry
No

Groups and cohorts

  • Cardiac surgery patients

    In order to be eligible to participate in this study, a participant must meet all of the following criteria: * Adult patients (18 years or older) * Use of central cannulated CPB through median sternotomy * Patients undergoing valve surgery or a supracoronary ascending aorta replacement * Good LVEF and RVF * LAVI \< 50 ml/m2, and right atrial volume index (RAVI) \< 45 ml/m2,

06

What researchers measure

Primary outcomes

  1. TVD (Total Vessel Density)

    The number of small blood vessels (\< 20 μm) in a given area. (Vessel density in #/area)

    Time frame: Intraoperatively

  2. PVD (Perfused Vessel Density)

    The number of small blood vessels that show perfusion, defined by a flow score of 2 or higher (moderate to normal flow). (Perfusion vessel density in #/area)

    Time frame: Intraoperatively

  3. PVD (Perfused Vessel Density)

    The ratio of total vessel length to the length of perfused vessels. (Ratio)

    Time frame: Intraoperatively

  4. MFI (Microvascular Flow Index)

    A semi-quantitative measure that evaluates flow in the capillary perfusion. (Flow score)

    Time frame: Intraoperatively

  5. HI (Heterogenity Index)

    The degree of variation in capillary perfusion flow between different areas, calculated as the difference between the highest and lowest MFI, divided by the average MFI. (Variation index)

    Time frame: Intraoperatively

Secondary outcomes

  1. Demographic information: Age

    Reported in years.

    Time frame: Preoperatively

  2. Demographic Information: Gender

    Categorized as male/female/other.

    Time frame: Preoperatively

  3. Demographic Information: Body Mass Index (BMI)

    Calculated as weight (kg) divided by height squared (m²). Reported in kg/m²

    Time frame: Preoperatively

  4. Demographic Information: Medical History

    Presence or absence of pre-existing conditions, such as hypertension, diabetes, prior heart surgeries; each condition reported as a separate categorical variable (yes/no).

    Time frame: Preoperatively

  5. Demographic Information: Comorbidities

    Presence or absence of vascular disease other than coronary artery disease, kidney dysfunction, pulmonary disease; each as separate categorical variables.

    Time frame: Preoperateively

  6. Surgical Variables: Type of Underlying Pathology

    Described separately for valve regurgitation, valve stenosis, aneurysm; categorical variable.

    Time frame: Preoperatively

  7. LV Unloading Variables: TVD (Total Vessel Density, # vessels per area)

    Capillary perfusion parameters measured separately, as they have different units and scales, consistent with primary objectives: Each perfusion parameter is reported separately for conditions with and without LV unloading.

    Time frame: Intraoperatively

  8. LV Unloading Variables: PVD (Perfused Vessel Density, # vessels per area)

    Capillary perfusion parameters measured separately, as they have different units and scales, consistent with primary objectives: Each perfusion parameter is reported separately for conditions with and without LV unloading.

    Time frame: Intraoperatively

  9. LV Unloading Variables: PPV (Proportion of Perfused Vessels, ratio)

    Capillary perfusion parameters measured separately, as they have different units and scales, consistent with primary objectives: Each perfusion parameter is reported separately for conditions with and without LV unloading.

    Time frame: Intraoperatively

  10. LV Unloading Variables: MFI (Microvascular Flow Index, semi-quantitative score)

    Capillary perfusion parameters measured separately, as they have different units and scales, consistent with primary objectives: Each perfusion parameter is reported separately for conditions with and without LV unloading.

    Time frame: Intraoperatively

  11. LV Unloading Variables: - HI (Heterogeneity Index, variation ratio)

    Capillary perfusion parameters measured separately, as they have different units and scales, consistent with primary objectives: Each perfusion parameter is reported separately for conditions with and without LV unloading.

    Time frame: Intraoperatively

07

Study locations

1 of 1 sites recruiting
  • Amsterdam Univeristy Medical Center
    Amsterdam, North Holland 1105 AZ, Netherlands
    Recruiting
08

References and documents

Individual participant data

Plan to share: Undecided — Depending on the outcome

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Start is estimated for Nov 2026; primary completion for Jun 2028, 18 months later.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 4, 2026: start Oct 2025 → Nov 2026, primary completion Jun 2026 → Jun 2028 and completion Oct 2026 → Oct 2029.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Aug 13, 2025
First posted
Aug 22, 2025
StartEst.
Nov 2, 2026was Oct 2025
Primary completionEst.
Jun 1, 2028was Jun 2026
CompletionEst.
Oct 1, 2029was Oct 2026
Last update
Nov 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Nov 4, 2026
Sites
1 site added — first site in Netherlands
Show site
  • Amsterdam Univeristy Medical Center · Amsterdam, Netherlands
Nov 4, 2026
Start date
Oct 1, 2025→Nov 2, 2026
Nov 4, 2026
Primary completion
Jun 1, 2026→Jun 1, 2028
Nov 4, 2026
Study completion
Oct 1, 2026→Oct 1, 2029
Nov 4, 2026
Show all 1 update
  1. Nov 4, 2026
    Not yet recruiting→Recruiting
    1 site added — first site in Netherlands
    Show site
    • Amsterdam Univeristy Medical Center · Amsterdam, Netherlands
    Start date Oct 1, 2025→Nov 2, 2026
    Primary completion Jun 1, 2026→Jun 1, 2028
    Study completion Oct 1, 2026→Oct 1, 2029
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07135700
Responsible party
Ufuk Baldan (Resident Cardiac Surgery. MD, Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)) — Principal investigator
First posted
Aug 22, 2025
Start date
Nov 2, 2026 (estimated)
Primary completion
Jun 1, 2028 (estimated)
Completion
Oct 1, 2029 (estimated)
Last update
Nov 4, 2026

Study contacts

Bahaeddin Ufuk Baldan, DR MD
Contact
b.u.baldan@amsterdamumc.nl
+31640001607

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion